CORRECTED VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 33/24, 38/00

A3

(11) International Publication Number: WO 98/48785

(43) International Publication Date: 5 November 1998 (05.11.98)

(21) International Application Number: PCT/US98/08684

(22) International Filing Date: 29 April 1998 (29.04.98)

(30) Priority Data:
60/044,394 29 April 1997 (29.04.97) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/044,394 (CIP)
Filed on 29 April 1997 (29.04.97)

(71) Applicants *(for all designated States except US)*: KENNETH BLUM, INC. [US/US]; 1211 Lost Stone, San Antonio, TX 78758 (US). BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 221 West 7th Street, Austin, TX 78701 (US). CITY OF HOPE NATIONAL MEDICAL CENTER [US/US]; 1500 East Duarte Road, Duarte, CA 91010–0269 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BLUM, Kenneth [US/US]; 1211 Lost Stone, San Antonio, TX 78258 (US). COMINGS, David, E. [US/US]; 59 Crestview Court, Duarte, CA 91010 (US). IVY, John, L. [US/US]; 10405 Skyflower Drive, Austin, TX 78759 (US).

(74) Agent: HODGINS, Daniel, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
1 April 1999 (01.04.99)

(54) Title: ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT

(57) Abstract

Enhancement of attentional processing is attained by administration of an endorphinase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non–addictive. Use of the dopamine precursors L–phenylalanine, or L–Tyrosine, the enkephalinase inhibitor D–phenylalanine, and/or the serotonin precursor –hydroxytryptophan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.

*(Referred to in PCT Gazette No. 20/1999, Section II)